Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis - why cardiovascular risk factors do not equate to overt risk.
Anna Felis-GiemzaMateusz MoskalKrzysztof ProcZbigniew GuzeraMarcin StajszczykKarolina PalejKornelia ChmurzyńskaPiotr WilandKrzysztof BatkoBogdan BatkoPublished in: Reumatologia (2024)
Tofacitinib demonstrated high retention rates and a favorable safety profile in RA patients, including those with traditional CV risk factors. Tofacitinib may be a valuable treatment option for RA patients when combined with individualized CV risk management. Further studies are warranted to explore the long-term effects of TOFA and its CV impact in larger populations.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- cardiovascular risk factors
- risk factors
- newly diagnosed
- ejection fraction
- chronic kidney disease
- disease activity
- peritoneal dialysis
- metabolic syndrome
- clinical trial
- cardiovascular disease
- systemic lupus erythematosus
- ulcerative colitis
- replacement therapy
- double blind